CervoMed Appoints Life Sciences Business Strategy Expert David Quigley To Its Board Of Directors To Support Long-Term Growth and Innovation

CervoMed Inc., a clinical-stage biotechnology company developing therapies for age-related brain disorders, has announced the appointment of David Quigley to its Board of Directors. Mr. Quigley is a highly experienced executive and former Senior Partner at McKinsey & Company, where he led the firm’s Life Sciences and Private Equity practices. His addition to the Board comes as CervoMed approaches key milestones, including receiving feedback from the U.S. Food and Drug Administration (FDA) on the design of its planned Phase 3 trial for patients with dementia with Lewy bodies (DLB), expected in the fourth quarter of 2025.

Joshua Boger, Ph.D., Chair of the CervoMed Board of Directors and founder of Vertex Pharmaceuticals, welcomed the appointment, noting that David Quigley’s strategic vision and commercial expertise will be instrumental as the company continues to advance neflamapimod toward major development milestones. He added that Quigley’s strong background in business strategy, finance, and his deep network within the pharmaceutical and private equity sectors will help drive CervoMed’s mission forward and enhance value for both patients and shareholders.

John Alam, M.D., President and Chief Executive Officer of CervoMed, also commented on the appointment, stating that David’s extensive industry knowledge and track record in supporting pipeline development, commercialization, partnerships, and mergers and acquisitions will be invaluable as the company prepares for its planned Phase 3 program in DLB and explores broader strategic growth opportunities.

In response to his appointment, Mr. Quigley expressed enthusiasm about joining CervoMed’s Board during what he described as a pivotal time for the company. He highlighted the strong Phase 2b clinical results for neflamapimod and shared his belief in its potential to become a first-in-class treatment for dementia with Lewy bodies. He added that he looks forward to collaborating with CervoMed’s leadership and Board to advance this promising program and maximize its potential for patients and investors alike.

David Quigley’s career at McKinsey & Company spanned more than 25 years, during which he served as a Senior Partner from 2010 to 2025. He held several key leadership roles, including Global Head of Private Capital (Private Equity), North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. Beyond his corporate achievements, he has been a guest lecturer in Life Sciences at Columbia University’s Mailman School of Public Health. Mr. Quigley holds a Bachelor of Arts from University College Dublin, a Master of Science from Queen’s University Belfast, and an MBA from INSEAD.

With his extensive experience and strategic insight, David Quigley’s appointment further strengthens CervoMed’s leadership team as the company moves forward with the late-stage development of neflamapimod and continues its mission to bring innovative treatments to patients suffering from age-related neurological disorders.